Search

Displaying results 7291 - 7300 of 10000 in total
  1. Drug

    Lorcinadol

    go.drugbank.com/drugs/DB21160
    Experimental

    Lorcinadol is a small molecule drug. The usage of the INN stem '-adol/-adol-' in the name indicates that Lorcinadol is a analgesic. Lorcinadol has a monoisotopic molecular weight of 314.13 Da.

  2. Drug

    Linarotene

    go.drugbank.com/drugs/DB21165
    Experimental

    Linarotene is a small molecule drug. The usage of the INN stem '-arotene' in the name indicates that Linarotene is a arotinoid derivative. Linarotene has a monoisotopic molecular weight of 398.2 Da.

  3. Drug

    Enrasentan

    go.drugbank.com/drugs/DB06460
    Experimental

  4. Drug

    Amdoxovir

    go.drugbank.com/drugs/DB06619
    Investigational

  5. Drug

    Capravirine

    go.drugbank.com/drugs/DB08502
    Investigational

  6. Drug

    Birtamimab

    go.drugbank.com/drugs/DB16414
    Investigational

    Birtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis).

  7. Drug

    Ancitabine

    go.drugbank.com/drugs/DB20595
    Experimental

    The usage of the INN stem '-citabine' in the name indicates that Ancitabine is a nucleoside antiviral or antineoplastic agent, cytarabine or azacitidine derivative. … Ancitabine is a small molecule drug.

  8. Drug

    Galocitabine

    go.drugbank.com/drugs/DB21373
    Experimental

    The usage of the INN stem '-citabine' in the name indicates that Galocitabine is a nucleoside antiviral or antineoplastic agent, cytarabine or azacitidine derivative. … Galocitabine is a small molecule drug.

  9. Drug

    SYNB1020

    go.drugbank.com/drugs/DB17667
    Investigational

    discontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. … It was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer

  10. Drug

    Alipogene tiparvovec

    go.drugbank.com/drugs/DB13521
    Approved

    It is being investigated for the treatment of lipoprotein lipase (LPL) deficiency.[A259796, A259801, A259806, A259811] … Alipogene tiparvovec is an adeno-associated viral vector of serotype 1-based gene therapy that delivers the Ser(447)X variant of the human lipoprotein lipase (LPL) gene.